Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin Lymphoma with progressive disease during or at the end of the previous therapy, as defined by the IWG criteria.~* Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin Lymphoma.~* Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.~* Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging.~* A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at least 2 cm in diameter on a CT scan.~* Patient should have had at least one line of prior chemotherapy. Patients relapsing after treatment with radiation therapy alone are not eligible.~* Age \> than or equal to 18 years.~* Both men and women and members of all races and ethnic groups are eligible for this trial.~* Women must not be pregnant or breast-feeding due to lack of information about the safety of administration of Temsirolimus in pregnant and lactating patients. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.~* Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of pregnancy prevention.~* Patient must have a SWOG performance status between 0-2.~* Patient must have no prior treatment with an m-TOR inhibitor.~* Patient must not have active infections at the time of registration.~* Laboratory studies should be obtained within two weeks of study registration except where noted otherwise. Allowable laboratory values are listed below:~* Absolute neutrophil count \> than or equal 1,000/mm3~* Hemoglobin \> than or equal 8 gm/dL~* Platelets \> than or equal 75,000/mm3~* Serum creatinine \< than or equal to two times the upper limit of normal. Creatinine should be measured within seven days of registration.~* Total serum bilirubin \< than or equal to ≤ 1.5 times the upper limit of normal. Total bilirubin should be measured within seven days of registration.~* AST (SGOT) \< than or equal to 3 times the upper limit of normal.~* ALT (SGPT) \< than or equal to 3 times the upper limit of normal.~* Fasting total cholesterol \< than or equal to 350 mg/dL.~* Fasting triglyceride level \< than or equal to 400 mg/dL.~* Patient must have a life expectancy of three months.~Exclusion Criteria:~* Patient must not have received prior allogeneic stem cell transplantation. Prior autologous stem cell transplantation more than six months prior to registration is acceptable.~* Patient must not have received prior chemotherapy, biologic therapy or radiation within three weeks prior to registration, and should have recovered from toxicities of prior therapy (to Grade 0 or 1).~* Patient must not have evidence of active CNS disease.~* Patient must not have an uncontrolled comorbid disease, including hyperlipidemia, hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia~* Patient must not have a psychiatric illness or social situation that would limit compliance with study requirements.~* Patient must have a life expectancy of three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).